Galderma Group AG Website

Galderma Group AG

SWX-GALD

Company Overview

Galderma Group AG is engaged in cosmetic industry. Its segment includes Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.

  • Name

    Galderma Group AG

  • CEO

    Flemming Ornskov

  • Website

    www.galderma.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1981

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Galderma’s sizable innovation pipeline should translate into accelerated revenue growth and EBITDA margin accretion over the midterm.

  • Galderma has a diversified portfolio across fast-growing segments of the dermatology market and is less exposed to patent cliffs compared with its pharmaceutical competitors, as 90% of sales are paid by consumers out of pocket.

  • Galderma’s balance sheet has been strengthened following the IPO, which should allow the company more flexibility in future capital allocation decisions.

Bears Say

  • The agreement with Ipsen for the current neuromodulator portfolio features stepped royalties that have been weighing on margins and may limit the company in pursuing volume market share growth.

  • The prescription oral and topical drug portfolio represents a drag on growth given increased pressure from the over-the-counter market segment.

  • Competitive pressure has been increasing in recent years in neuromodulators with additional drug launches and aggressive marketing campaigns that could hurt Galderma's market share over the long term.

Source: Morningstar Analysis - Oct 23, 2025
SWX:GALD